Skip to main content
Innate Pharma S.A. (EPA:IPH)
France flag France · Delayed Price · Currency is EUR
1.672
-0.008 (-0.48%)
At close: Dec 5, 2025

Innate Pharma Revenue

Innate Pharma had revenue of 4.86M EUR in the half year ending June 30, 2025, a decrease of -87.91%. This brings the company's revenue in the last twelve months to 12.64M, down -62.60% year-over-year. In the year 2024, Innate Pharma had annual revenue of 20.12M, down -67.36%.

Revenue (ttm)
12.64M
Revenue Growth
-62.60%
P/S Ratio
12.20
Revenue / Employee
72.62K
Employees
181
Market Cap
154.10M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202420.12M-41.52M-67.36%
Dec 31, 202361.64M3.97M6.88%
Dec 31, 202257.67M32.97M133.47%
Dec 31, 202124.70M-45.07M-64.60%
Dec 31, 202069.77M-15.68M-18.35%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
EssilorLuxottica Société anonyme 27.24B
Sanofi 45.93B
Sartorius Stedim Biotech 2.95B
bioMérieux 4.12B
Eurofins Scientific SE 7.14B
Ipsen 3.76B
ABIVAX Société Anonyme 6.02M
Virbac 1.43B
Revenue Rankings

Innate Pharma News

More News